PX-3

PX-3
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Class B; Illegal in Sweden;
Identifiers
	IUPAC name N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide;
CAS Number	1185887-14-2;
PubChem CID	44206137;
ChemSpider	48063640;
UNII	3877T06H05;
CompTox Dashboard (EPA)	DTXSID201009998 ;
Chemical and physical data
Formula	C24H28N4O2
Molar mass	404.514 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)[C@H](Cc1ccccc1)NC(=O)c2nn(CC3CCCCC3)c4ccccc24;
	InChI InChI=1S/C24H28N4O2/c25-23(29)20(15-17-9-3-1-4-10-17)26-24(30)22-19-13-7-8-14-21(19)28(27-22)16-18-11-5-2-6-12-18/h1,3-4,7-10,13-14,18,20H,2,5-6,11-12,15-16H2,(H2,25,29)(H,26,30)/t20-/m0/s1; Key:DMHWDSGURMXMGE-FQEVSTJZSA-N;

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of K_i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.^[1]^[2]^[3]^[4]

Quick Facts Legal status, Identifiers ...

Legality